Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neurocognitive Outcome of Conformal Whole Brain Radiotherapy With Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial

NCT04801342 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT04801342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04801342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neurocognitive Outcome of Conformal Whole Brain Radiotherapy With Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2021
Completion date
February 28, 2025
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm to brain